NIAID’s Clinical Trial to Develop RSV Vaccine

NIAID’s Clinical Trial to Develop RSV Vaccine

Agency: 
Dept. of Health and Human Services

The National Institute of Allergy and Infectious Diseases (NIAID) began a clinical trial for an investigational vaccine to protect against respiratory syncytial virus (RSV). The Phase 1 study will enroll a small group of healthy adult volunteers to examine the safety of an intranasal vaccine and its ability to induce an immune response. RSV, a common virus, causes mild, cold-like symptoms that resolve within two weeks. However, this virus can cause severe symptoms, especially among infants and young children. Each year, an estimated 57,000 children under the age of five years are hospitalized in the United States due to RSV infection.

The Dale and Betty Bumpers Vaccine Research Center (VRC) at the National Institutes of Health (NIH) was established to facilitate research in vaccine development. The VRC is improving global health by developing effective vaccines. Established by President Clinton as part of an initiative to develop an AIDS vaccine, the VRC is a unique venture within the NIH intramural research program.

Category: 
Lab Spotlight
Region: 
Mid-Atlantic